BACK

Austrian Biotech Innovators: Top 10 Early-Stage Life Sciences Startups

Exploring the booming biotech scene in Austria

Austria’s biotech and life sciences sector has emerged as a key player in global healthcare innovation. With over 1000 life sciences companies, including biotech, pharmaceutical, and medical technology enterprises, Austria boasts a vibrant ecosystem supported by major industry players.

The country excels in areas such as cancer research, gene therapy, and medical product development. Governmental funding agencies, such as the Austrian Research Promotion Agency (FFG) and the Austrian Science Fund (FWF), provide crucial financial backing, fostering an environment where both seasoned and budding innovators can thrive.

Austria’s strength also lies in its cutting-edge infrastructure. Accelerators offer state-of-the-art modular laboratory spaces for startups, enabling them to conduct advanced research without the massive upfront costs typically associated with such facilities.

How Austrian Life Sciences Startups Are Transforming Global Healthcare

Revolutionizing Treatment Scalability: Austrian biotech startups are enhancing the scalability of cell therapies, biologics, and protein conjugation technologies, making previously inaccessible biotech treatments more available.
Accelerating Drug Discovery: Leveraging AI technologies, organoids, and 3D tissue models, startups are speeding up drug discovery processes for various diseases, including heart conditions and neurological disorders.
Improving Diagnostic Precision: Startups are using technologies like electromagnetic fields to improve diagnostic accuracy, allowing for early and more precise detection of complex diseases.
Reducing Healthcare Costs: Automation, novel platforms, and advanced tools are reducing production and operational costs, making biotech therapies more affordable.
Personalizing Healthcare: By tailoring treatments to individual patients, Austrian innovators are advancing precision medicine, leading to better health outcomes globally.
Expanding Global Healthcare Access: Their technologies are bringing life-saving biotech treatments and diagnostics to underserved populations worldwide, improving overall healthcare equity.

Top 10 Early-Stage Life Sciences Startups Leveraging Biotechnology in Austria

These innovators leverage biotechnology to address challenges in life sciences, particularly in health, diagnostics, and therapeutic innovations.

1. 1. Sarcura - Revolutionizing cell therapy manufacturing
  - Establishment year - 2019
  - Headquarters - Klosterneuburg, Niederosterreich, Austria
  - Founders - Daniela Buchmayr, Erwin Gorjup
  - Latest Funding(in USD) - $ 7.3M
  - Investor/s - HCVC, Nina Capital, xista science ventures, NovaCapital, tecnet equity
2. Sarcura GmbH is revolutionizing cell therapy manufacturing through an autonomous, modular platform that leverages semiconductor chip technology and microfluidics for real-time, cellular-level process control. By automating production and reducing costs by up to 10x, they aim to make life-saving treatments like CAR-T therapy more accessible and scalable. With clinical trials showing up to 85% remission in severe blood cancers, Sarcura's innovations promise to significantly boost production capacity and broaden therapeutic applications beyond oncology.
1. 2. HeartBeat.bio - Advancing cardiac drug discovery through organoids.
  - Establishment year - 2021
  - Headquarters - Vienna, Wien, Austria
  - Founders - Michael Krebs(CEO), Florian Fuchs(CTO)
  - Latest Funding(in USD) - $ 4.8M
  - Investor/s - aws Gründungsfonds, Tensor Ventures, red-stars.com, INVEST AG, i&i Biotech Fund
2. HeartBeat.bio is a biotech company revolutionizing cardiac drug discovery with its Cardioid Drug Discovery Platform, which uses iPSC-derived cardiac organoids to model heart diseases like cardiomyopathies and myocardial infarction. By combining advanced 3D heart tissue models with AI-driven data analysis and scalable automation, the company enhances drug screening accuracy, speed, and cost-efficiency. Focused on heart failure and related conditions, HeartBeat.bio aims to build a broad portfolio of pre-clinical assets to address the unmet medical needs of over 30 million patients globally.
1. 3. a:head bio - Transforming CNS drug discovery
  - Establishment year - 2019
  - Headquarters - Vienna, Wien, Austria
  - Founders - Oliver Szolar Ph.D, Madeline Lancaster
  - Latest Funding(in USD) - $ 4.5M
  - Investor/s - red-stars.com
2. a:head bio is revolutionizing CNS drug discovery by utilizing human cerebral organoids, 3D tissue cultures that mimic the human brain, for the development of novel therapeutics. Their proprietary platform integrates AI-driven analysis and cutting-edge technologies like gene editing and cell reprogramming to recreate human neurological diseases and identify potential treatments. This human-focused approach eliminates the need for animal models, offering unprecedented predictive accuracy and providing hope for patients with currently unmet medical needs.
1. 4. VALANX Biotech - Innovating protein conjugation for advanced biologics.
  - Establishment year - 2017
  - Headquarters - Graz, Steiermark, Austria
  - Founders - Michael Lukesch
  - Latest Funding(in USD) - $ 2.5M
  - Investor/s - SOSV, xista science ventures, austria Wirtschaftsservice (aws), tecnet equity, RebelBio
2. VALANX Biotech specializes in developing a proprietary platform for site-specific protein conjugation, enabling precise control over conjugation sites and numbers on target proteins. Utilizing synthetic biology and genetic code expansion, their technology enhances biologics' stability, efficacy, and therapeutic potential while reducing aggregation and immunogenicity. VALANX is advancing cutting-edge biologics for therapeutic, diagnostic, and biocatalysis applications, revolutionizing protein conjugation to improve product quality and outcomes.
1. 5. Cellectric Biosciences - Cell manipulation for diagnostics.
  - Establishment year - 2021
  - Headquarters - Vienna
  - Founders - Terje Wimberger and Klemens Wassermann
  - Latest Funding(in USD) - $ 1.08M
  - Investor/s - Forschungsförderungsgesellschaft, Business Angels, and xista science ventures
2. Cellectric is a biotech startup developing an automated cell manipulation platform using electromagnetic fields to enhance precision in life science applications. Their technology enables fast and selective detection of analytes in complex human samples, addressing key challenges in healthcare diagnostics, such as accelerated sepsis diagnosis. By integrating dielectric filter technology, they provide unmatched specificity and throughput, helping healthcare partners save lives and reduce costs.
1. 6. Biolyz - Non-invasive bio-analytics for health diagnostics.
  - Establishment year - 2021
  - Headquarters - Tulln, Niederosterreich, Austria
  - Founders - Marlon Millard
  - Latest Funding(in USD) - $ 1M
  - Investor/s - Atrinum. | Ventures
2. Biolyz leverages non-invasive bio-analytics to provide data-driven recommendations for performance improvement and injury prevention. With advanced high-throughput proteomics technology, they offer precise protein analysis services, driving innovation in sports and health diagnostics.
1. 7. Solgate - Targeting metabolic diseases via transporter modulation.
  - Establishment year - 2020
  - Headquarters - Klosterneuburg, Lower Austria
  - Founders - Ariel Bensimon Ph.D, Gaia Novarino Ph.D, Giulio Superti-Furga Ph.D, Stefan Kubicek Ph.D, and Georg Winter Ph.D
  - Latest Funding(in USD) - NA
  - Investor/s - Austria Wirtschaftsservice, Lansdowne Capital, Schütz Family Office, and xista science ventures
2. Solgate focuses on developing drug candidates targeting Solute Carrier transporters to address metabolic imbalances associated with various diseases. By leveraging expertise in metabolism, disease biology, and cutting-edge drug discovery technologies, they aim to modulate nutrient flow across cell membranes, influencing health outcomes. Their innovative approach positions membrane transporters as key drug targets to improve patient lives through metabolic restoration.
1. 8. HD Immune - Pioneering Monoclonal antibody treatment for Huntington’s Disease.
  - Establishment year - 2023
  - Headquarters - Vienna, Wien, Austria
  - Founders - Stefan Bartl Ph.D, Lionel Wightman Ph.D
  - Latest Funding(in USD) - NA
  - Investor/s - austria Wirtschaftsservice (aws), Austrian Angel Investors Association
2. HD Immune is focused on developing a first-in-class monoclonal antibody treatment for Huntington's Disease, a fatal neurodegenerative disorder with no current cure. Leveraging proprietary research, the company targets the mutant huntingtin protein, aiming to block its intercellular transmission and slow disease progression. With a strategy based on validated scientific results, HD Immune offers a novel therapeutic approach, potentially revolutionizing treatment options for Huntington's patients.
1. 9. Phoenestra GmbH - Scaling cell therapy with bioprocessing innovations.
  - Establishment year - 2021
  - Headquarters - Linz, Austria
  - Founders - Klaus Graumann Ph.D, Otto Kanzler
  - Latest Funding(in USD) - NA
  - Investor/s - tech2b
2. Phoenestra is advancing scalable bioprocessing for cell- and vesicle-based products, addressing challenges in cell and gene therapy manufacturing. Their EVscale™ platform enables the production of biologically active extracellular vesicles at clinically relevant scales, while partnerships with Evercyte and TAmiRNA support GMP-grade cell line development. By bridging the industrialization gap, Phoenestra is enhancing access to innovative therapies.
1. 10. Luminous Labs - Optimizing health through red light therapy.
  - Establishment year - 2021
  - Headquarters - Graz, Steiermark, Austria
  - Founders - Barbara Sekulovska, BA MSc, Thomas Lechner, MA MLL
  - Latest Funding(in USD) - NA
  - Investor/s - Biogena
2. Luminousred is a pioneering company in the biohacking space red light therapy to drive cellular regeneration and enhance mitochondrial function. Through its proprietary CellLight™ technology, the company applies biophotonics to stimulate ATP production at the cellular level, promoting tissue repair, reducing inflammation, and optimizing cellular metabolism. Rooted in cutting-edge biotech research, Luminous Labs integrates light-based therapeutic interventions into health solutions, offering a non-invasive, scientifically-backed approach to improving cellular function and advancing wellness.

Conclusion: The Future of Biotech in Austria

With Austria’s biotech ecosystem continually evolving, its contribution to global healthcare is set to grow exponentially. The collaborative efforts between academia, government, and industry ensure that Austrian startups have the support and resources needed to drive the next generation of medical advancements. As these early-stage innovators mature, their impact on reducing healthcare costs, enhancing patient care, and expanding treatment access will be felt worldwide.

Explore More About Austria’s Thriving Startup Ecosystem

To explore further insights into such trends and emerging startups, visit Zefyron

◾About Zefyron - Zefyron offers a comprehensive database with 2M startups and 350K investors, facilitating easy connections and networking. Our platform streamlines fundraising and investor scouting with tools like pitch decks and valuations. Users can efficiently manage portfolios, gain insights, host events, and track industry trends for informed decisions and meaningful collaborations.